NASDAQ:CYCN Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis $2.95 +0.06 (+2.08%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Cyclerion Therapeutics Stock (NASDAQ:CYCN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cyclerion Therapeutics alerts:Sign Up Key Stats Today's Range$2.88▼$3.7450-Day Range$2.43▼$3.1652-Week Range$1.75▼$5.25Volume125,048 shsAverage Volume6,589 shsMarket Capitalization$7.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Cyclerion Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks18th Percentile Overall ScoreCYCN MarketRank™: Cyclerion Therapeutics scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cyclerion Therapeutics.Read more about Cyclerion Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCyclerion Therapeutics has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cyclerion Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.58% of the float of Cyclerion Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclerion Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclerion Therapeutics has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCyclerion Therapeutics does not currently pay a dividend.Dividend GrowthCyclerion Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.58% of the float of Cyclerion Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclerion Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclerion Therapeutics has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Cyclerion Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cyclerion Therapeutics' insider trading history. Receive CYCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclerion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYCN Stock News HeadlinesRegina Graul, Ph.D., Promoted to Chief Executive OfficerAugust 7, 2024 | globenewswire.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q1 2024May 8, 2024 | investorplace.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.November 2, 2024 | Chaikin Analytics (Ad)Sage Therapeutics Stock (NASDAQ:SAGE), Quotes and News SummaryApril 28, 2024 | benzinga.comCyclerion Therapeutics Inc Ordinary Shares CYCNApril 21, 2024 | morningstar.comCYCN Stock Earnings: Cyclerion Therapeutics Reported Results for Q4 2023April 5, 2024 | investorplace.comCyclerion Therapeutics Inc (CYCN)March 6, 2024 | investing.comCyclerion Therapeutics, Inc. (CYCN)February 29, 2024 | uk.finance.yahoo.comSee More Headlines CYCN Stock Analysis - Frequently Asked Questions How have CYCN shares performed this year? Cyclerion Therapeutics' stock was trading at $3.35 at the beginning of 2024. Since then, CYCN shares have decreased by 11.9% and is now trading at $2.95. View the best growth stocks for 2024 here. How were Cyclerion Therapeutics' earnings last quarter? Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.53) EPS for the quarter. When did Cyclerion Therapeutics' stock split? Shares of Cyclerion Therapeutics reverse split before market open on Tuesday, May 16th 2023. The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Cyclerion Therapeutics? Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cyclerion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), General Electric (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/07/2024Today11/02/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYCN CUSIPN/A CIK1755237 Webwww.cyclerion.com Phone(857) 327-8778FaxN/AEmployees30Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.84% Return on Assets-57.28% Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio3.68 Sales & Book Value Annual Sales$1.62 million Price / Sales4.93 Cash FlowN/A Price / Cash FlowN/A Book Value$4.62 per share Price / Book0.64Miscellaneous Outstanding Shares2,710,000Free Float1,732,000Market Cap$7.99 million OptionableNo Data Beta1.93 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:CYCN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.